XORTX Therapeutics Inc. - Common Shares (XRTX)
XRTX moved a median of 0.00% 30 minutes after news, and -0.95% by the close. How XRTX actually reacts to news — the realized, point-in-time move the market made, measured across 228 labeled events over the last three years with zero look-ahead.
XRTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 22% | 179 |
| 30-min | 0.00% | 43% | 206 |
| 60-min | 0.00% | 38% | 219 |
| to close | -0.95% | 39% | 225 |
| Middle 50% of XRTX reactions | -2.62% to +1.40% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 228 |
Half of all XORTX Therapeutics Inc. - Common Shares news events land between -2.62% and +1.40% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when XRTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to XRTX's baseline. Nothing else.
Recent XRTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K XORTX Therapeutics Inc. For: Oct 08 | SEC filing · Form 6-K | SEC EDGAR | -5.00% | -31.55% | |
| XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout | Press release | GlobeNewswire | -5.00% | -31.55% | |
| Form 6-K XORTX Therapeutics Inc. For: Sep 18 | SEC filing · Form 6-K | SEC EDGAR | -4.50% | -4.00% | |
| XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity | Press release | GlobeNewswire | -4.50% | -4.00% | |
| Form 6-K XORTX Therapeutics Inc. For: Sep 10 | SEC filing · Form 6-K | SEC EDGAR | -0.83% | -3.32% | |
| XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™ | Press release | GlobeNewswire | -0.83% | -3.32% | |
| Form 6-K XORTX Therapeutics Inc. For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | — | -10.59% | |
| XORTX Re-Engages Investor Relations Program | Press release | GlobeNewswire | — | -5.35% | |
| Form 6-K XORTX Therapeutics Inc. For: Sep 04 | SEC filing · Form 6-K | SEC EDGAR | -5.97% | -4.94% | |
| Form 6-K XORTX Therapeutics Inc. For: Aug 28 | SEC filing · Form 6-K | SEC EDGAR | -1.70% | -0.51% | |
| XORTX Announces Termination and Postponement of Investor Relations Program | Press release | GlobeNewswire | -1.70% | -0.51% | |
| Form 6-K XORTX Therapeutics Inc. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.96% | |
| Form 6-K XORTX Therapeutics Inc. For: Jul 31 | SEC filing · Form 6-K | SEC EDGAR | +0.47% | +1.89% | |
| XORTX Announces Director Resignation | Press release | GlobeNewswire | +0.00% | +2.90% | |
| Form 6-K XORTX Therapeutics Inc. For: Jul 29 | SEC filing · Form 6-K | SEC EDGAR | — | +0.00% | |
| XORTX Appoints New Director | Press release | GlobeNewswire | — | +0.00% | |
| Form 6-K XORTX Therapeutics Inc. For: Jun 15 | SEC filing · Form 6-K | SEC EDGAR | -5.46% | -4.37% | |
| XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO | Press release | GlobeNewswire | -5.46% | -4.37% | |
| Form 6-K XORTX Therapeutics Inc. For: Jun 12 | SEC filing · Form 6-K | SEC EDGAR | -5.46% | -4.37% | |
| XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange | Press release | GlobeNewswire | -5.46% | -4.37% | |
| Form 6-K XORTX Therapeutics Inc. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -1.19% | -7.94% | |
| Form 6-K XORTX Therapeutics Inc. For: May 19 | SEC filing · Form 6-K | SEC EDGAR | -1.19% | -7.94% | |
| XORTX Announces Closing of US$5 Million Public Offering | Press release | GlobeNewswire | -1.19% | -7.94% | |
| E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering | Press release | GlobeNewswire | -0.78% | +0.78% | |
| Form 6-K XORTX Therapeutics Inc. For: May 14 | SEC filing · Form 6-K | SEC EDGAR | +4.39% | -1.95% | |
| Form EFFECT XORTX Therapeutics Inc. | SEC filing · Form EFFECT | SEC EDGAR | +4.39% | -1.95% | |
| XORTX Announces US$5 Million Public Offering | Press release | GlobeNewswire | +4.39% | -1.95% | |
| Form 6-K XORTX Therapeutics Inc. For: May 08 | SEC filing · Form 6-K | SEC EDGAR | +1.11% | -9.22% | |
| Form POS AM XORTX Therapeutics Inc. | SEC filing · Form POS | SEC EDGAR | — | +2.01% | |
| Form POS AM XORTX Therapeutics Inc. | SEC filing · Form POS | SEC EDGAR | +1.84% | +11.81% | |
| Form POS AM XORTX Therapeutics Inc. | SEC filing · Form POS | SEC EDGAR | +1.59% | +12.75% | |
| Form 6-K XORTX Therapeutics Inc. For: Apr 21 | SEC filing · Form 6-K | SEC EDGAR | -5.08% | -8.81% | |
| XORTX Meets Nasdaq Continued Listing Requirements | Press release | GlobeNewswire | -2.71% | -8.81% | |
| Form 6-K XORTX Therapeutics Inc. For: Apr 13 | SEC filing · Form 6-K | SEC EDGAR | +0.90% | +9.42% | |
| XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset | Press release | GlobeNewswire | -2.52% | -0.46% | |
| Form 6-K XORTX Therapeutics Inc. For: Apr 01 | SEC filing · Form 6-K | SEC EDGAR | — | +6.00% | |
| XORTX Confirms Effective Date of Share Consolidation | Press release | GlobeNewswire | — | +6.00% | |
| Form 6-K XORTX Therapeutics Inc. For: Mar 26 | SEC filing · Form 6-K | SEC EDGAR | -1.46% | +0.29% | |
| Form 6-K XORTX Therapeutics Inc. For: Mar 25 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -15.85% | |
| XORTX Announces Change of Effective Date of Share Consolidation | Press release | GlobeNewswire | -1.46% | +0.29% | |
| XORTX Announces Results of Annual and Special Meeting of Shareholders | Press release | GlobeNewswire | -1.46% | +0.29% | |
| XORTX Announces Share Consolidation | Press release | GlobeNewswire | +0.00% | -15.85% | |
| Form 6-K XORTX Therapeutics Inc. For: Mar 24 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -5.84% | |
| XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting | Press release | GlobeNewswire | +0.00% | -5.84% | |
| Form 20-F XORTX Therapeutics Inc. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.00% | -1.70% | |
| Form 6-K XORTX Therapeutics Inc. For: Mar 18 | SEC filing · Form 6-K | SEC EDGAR | — | +1.86% | |
| XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders | Press release | GlobeNewswire | +4.06% | +6.45% | |
| Form 6-K XORTX Therapeutics Inc. For: Mar 13 | SEC filing · Form 6-K | SEC EDGAR | — | +0.94% | |
| XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation | Press release | GlobeNewswire | +0.00% | -9.07% | |
| Form 6-K XORTX Therapeutics Inc. For: Mar 05 | SEC filing · Form 6-K | SEC EDGAR | -1.95% | +6.10% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the XRTX section they belong to.
Where else XRTX is measured.
XRTX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is XORTX Therapeutics Inc. - Common Shares's median reaction calculated?
Every labeled XRTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 228 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of XRTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does XRTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.